Abstract
of conflict of interest: In, Ho have consulting fees to disclose. Ali has consulting fees, grants, participation on a DSMB and payment/honoraria. Ch has a grant to disclose. Br has grants, support for meetings and receipt of drugs to disclose. Wa has participation in clinical trials to disclose. Zw a grant and receipt of drugs to disclose. has Alt, Ar, Ak, De, Go, Ha, Lo, Mc, Mo, Sc, Es have nothing to disclose.
Highlights
Safety and Outcomes of Inhalation Suspension for Pulmonary Disease pulmonary disease consist of an intensive phase of 2 to months of IV antibiotics combined with oral drugs
Through the NTM-net, we recruited physicians who were experienced in the use of Amikacin liposome inhalation suspension (ALIS) in M abscessus pulmonary disease
Most patients were initiated on ALIS because of toxicity of IV amikacin (n 1⁄4 10; 24.4%) and to strengthen the oral regimen in the continuation phase (n 1⁄4 6; 14.6%) for treatment of refractory M
Summary
Pulmonary Disease pulmonary disease consist of an intensive phase of 2 to months of IV antibiotics (including amikacin, imipenem or cefoxitin, and tigecycline) combined with oral drugs (including clofazimine, linezolid, azithromycin). The continuation phase consists of two or three oral antibiotics, preferably with proven in vitro activity, and inhaled amikacin.[1,2]. Amikacin liposome inhalation suspension (ALIS) allows for better biofilm and macrophage penetration[3] and is likely more effective than inhalation of the IV solution of the drug. We aimed to assess the safety and outcomes of compassionate use of ALIS in M abscessus pulmonary disease. To the Editor: Mycobacterium abscessus is an opportunistic pathogen notorious for its antibiotic resistance and poor treatment outcomes.[1] Treatment regimens for M abscessus
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
